News | February 12, 2020

Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance of New Drug Application and Priority Review for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors – FDA Grants Priority Review and sets PDUFA Date of August 13,...

News | February 19, 2020

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 19, 2020– Deciphera Pharmaceuticals, Inc. (Nasdaq:DCPH), a clinical-stage biopharmaceutical company focused on addressing key...

News | January 30, 2020

Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease NYX-458 is currently under evaluation in a Phase 2 study in patients with mild cognitive impairment associated...

News | January 10, 2020

Aptinyx Announces Pricing of Public Offering of Common Stock EVANSTON, Ill., Jan. 10, 2020 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system...

New | January 31, 2020

Kit Check’s Bluesight for Controlled Substances™ Named Category Leader for Drug Diversion Monitoring in 2020 Best in KLAS Report KLAS report ranks Kit Check as the top performer with 93.9 rating for consistently delivering on product support, customer loyalty and...

News | March 25, 2020

BrightInsight Announces Global Digital Health Partnership with AstraZeneca AstraZeneca selects the BrightInsight Platform to build and manage its digital health solutions within a regulatory-compliant environment SAN JOSE, Calif., March 25, 2020 (GLOBE NEWSWIRE)...